Holen Sie sich die Stockscreener-App
1.86
2.62%
-0.05
Handel nachbörslich:
1.90
0.04
+2.15%
Schlusskurs vom Vortag:
$1.91
Offen:
$1.9706
24-Stunden-Volumen:
4,378
Relative Volume:
0.15
Marktkapitalisierung:
$28.24M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.26M
KGV:
-1.5744
EPS:
-1.1814
Netto-Cashflow:
$-13.50M
1W Leistung:
-4.12%
1M Leistung:
-19.83%
6M Leistung:
-43.64%
1J Leistung:
-54.63%
1-Tages-Spanne:
$1.85
$1.9999
1-Wochen-Bereich:
$1.78
$1.9999
52-Wochen-Spanne:
$1.50
$5.275
Intensity Therapeutics Inc Stock (INTS) Company Profile
Firmenname
Intensity Therapeutics Inc
Sektor
Branche
Telefon
203-221-7381
Adresse
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Vergleichen Sie INTS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
1.86 | 28.24M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.59 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.14 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Intensity Therapeutics Inc Aktie (INTS) Neueste Nachrichten
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™ - PR Newswire UK
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™. - The Manila Times
IntercontinentalExchange price target lowered to $230 from $237 at BofA - Yahoo Finance
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Why Iridium Communications (IRDM) is a Top Value Stock for the Long-Term - Yahoo Finance
Soft Tissue Sarcoma Treatment Market Size in 7MM is expected - openPR.com
Insiders At Cencora Sold US$16m In Stock, Alluding To Potential Weakness - Yahoo Finance
Leading Factor Driving the Burkitt Lymphoma Therapeutics Market in 2025: Impact Of Rising HIV Incidence On ... - WhaTech
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment - openPR
Benchmark maintains Speculative Buy on Intensity Therapeutics By Investing.com - Investing.com South Africa
Benchmark maintains Speculative Buy on Intensity Therapeutics - Investing.com
Soft Tissue Neoplasms Treatment Market Size in 7MM is expected - openPR
Here is Why Growth Investors Should Buy Cencora (COR) Now - Yahoo Finance
Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment - Yahoo Finance
INTENSITY THERAPEUTICS Earnings Results: $INTS Reports Quarterly Earnings - Nasdaq
Small Number of Acne Products Recalled for Problematic Levels of Benzene - 69News WFMZ-TV
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update - Longview News-Journal
Tempest Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TPST - Benzinga
Bile Duct Neoplasms Treatment Market Size Report 2032 | Taewoong - openPR.com
Alpheus Medical Publishes Promising Early Clinical Results of Sonodynamic Therapy for the Treatment of Newly Diagnosed Glioblastomas - BioSpace
Equillium (NASDAQ:EQ) Stock Quotes, Forecast and News Summary - Benzinga
Thyroid Cancer Market Size to Reach USD 1,892.4 Million by 2035, Impelled by Advancements in Gene Therapy and Personalized Medicine - BioSpace
Grafapex Approved for Reduced-Intensity Stem Cell Transplants in AML and MDS Patients - Managed Healthcare Executive
Intensity Infrastucture Partners Launches Open Season for New Natural Gas Transmission Pipeline to Serve the Bakken Region - Yahoo Finance
Clinical Trials News Live Feed - StockTitan
Drug Monitoring Committee Authorizes Continuation of Intensity T - GuruFocus.com
Intensity Therapeutics' sarcoma trial proceeds after review By Investing.com - Investing.com Canada
Intensity Therapeutics' sarcoma trial proceeds after review - Investing.com India
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review - Nasdaq
Finanzdaten der Intensity Therapeutics Inc-Aktie (INTS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
1.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):